Favorable coverage decision for sensor-based blood glucose monitors (CGM and FGM) in Norway

Norway has a national system for the introduction of new health technologies within the specialist health service ("New Methods" framework) through either a national or hospital-based health technology assessment. This framework is mandatory for all innovations before being funded.

In June 2023, the simplified method assessment of sensor-based blood glucose monitors in type 1 diabetes was commissioned by the Ordering Forum for "New Methods" to the National Institute of Public Health (NIPH). Both continuous glucose monitoring (rtCGM) and flash glucose monitoring (FGM) were considered for the evaluation. 

In November 2023, the NIPH report was published, mainly based on the Danish Health Technology Council's (Behandlingsrådet) analysis of 2023. 

On December 11, 2023, the Decision Forum for "New Methods" made the following recommendations:

• Sensor-based glucose monitors should be introduced to adults with type 1 diabetes;
• The choice of the device must follow the current framework agreement in the tender and ranking for continuous glucose monitors and consumables.

Framework agreements are managed by the organization called Hospital Procurement HF (Sjukehusinnkjøp HF).

See more information in Norwegian here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.